First Fruit of the New Partnership: YHLO's Adventure in Tokyo

2020-09-18

Summary:YHLO recently achieved new achievements with our scientific partner in Covid-19 study.

In August 2020, Tatsuhiko KODAMA, emeritus professor of the University of Tokyo, has reported the latest clinical findings of human immune response against COVID-19 with the help of CLIA platform and SARS-CoV2 diagnostic kits from YHLO. 

According to the research team of Professor KODAMA's report, after analyzing the antibodies level of 15,772 patients submitted by 6 different institutes* including The University of Tokyo Hospital and Osaka University Hospital, they found out there is a significant difference of the IgG level between COVID-19 patients of different severities. Severely ill patients were found having a critically lower level of IgG, while moderately ill patients were found having the highest level of IgG compared to all other stages. It is hypothesized that the immune response might be inhibited by cytokine storm in severe COVID-19 patients.

Moreover, after applying the CLIA screens, the research team has discovered that the spike glycoprotein antibody against COVID-19 has a persistence of more than 150 days. Professor KODAMA indicates that the S antibody could be a potential target for COVID-19 vaccine development.

Moreover, after applying the CLIA screens, the research team has discovered that the spike glycoprotein antibody against COVID-19 has a persistence of more than 150 days. Professor KODAMA indicates that the S antibody could be a potential target for COVID-19 vaccine development.

Early in May, Research Center for Advanced Science and Technology, The University of Tokyo (RCAST) has initially imported the iFlash 3000 CLIA platform and SARS-CoV2 diagnostic kits from YHLO for large-scale COVID-19 diagnosis, which has established the first partnership between YHLO and RCAST.

Early in May, Research Center for Advanced Science and Technology, The University of Tokyo (RCAST) has initially imported the iFlash 3000 CLIA platform and SARS-CoV2 diagnostic kits from YHLO for large-scale COVID-19 diagnosis, which has established the first partnership between YHLO and RCAST.

*The involved institutes include: The University of Tokyo Hospital, Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Keio University Hospital, Osaka University Hospital, Kyoto Prefectural University, and The Tokyo Metropolitan Institute of Medical Science.

 

Reference:

https://www.asahi.com/articles/ASN6K64RKN6DULBJ00F.html

https://www.rcast.u-tokyo.ac.jp/ja/research/people/staff-kodama_tatsuhiko.html

https://www.youtube.com/watch?v=o_nllUM9UU4

 
Language
Search
亚辉龙

Join Us

关注我们

Wechat

Headquarter: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China

Follow YHLO

wechatwechat wechat wechat wechat

© 2020  Shenzhen YHLO Biotech Co., Ltd.  All rights reserved.  粤ICP备19040167号